Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells

Leukemia. 2019 Mar;33(3):766-771. doi: 10.1038/s41375-018-0278-7. Epub 2018 Oct 12.

Authors

Krista Kinneer¹, Matt Flynn², Suneetha B Thomas², John Meekin², Reena Varkey³, Xiaodong Xiao^{3

4}, Haihong Zhong², Shannon Breen², Paul G Hynes^{2

5}, Ryan Fleming³, Binyam Bezabeh^{3

6}, Cui Tracy Chen², Leslie Wetzel², Ruoyan Chen⁷, Nazzareno Dimasi³, Yu-Tzu Tai⁸, Kenneth C Anderson⁸, Ronald Herbst², Philip W Howard⁹, Elaine M Hurt², David A Tice²

Affiliations

¹ MedImmune, Oncology Research, Gaithersburg, MD, USA. [email protected].
² MedImmune, Oncology Research, Gaithersburg, MD, USA.
³ MedImmune, Antibody Discovery and Protein Engineering, Gaithersburg, MD, USA.
⁴ Bristol-Myers Squibb, Redwood City, CA, USA.
⁵ Cell Medica, London, UK.
⁶ Salubris Biotherapeutics, Gaithersburg, MD, USA.
⁷ MedImmune, Biosuperiors, Gaithersburg, MD, USA.
⁸ Dana-Farber Cancer Institute, Boston, MA, USA.
⁹ Spirogen, London, UK.

PMID: 30315237
DOI: 10.1038/s41375-018-0278-7

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies / immunology*
B-Cell Maturation Antigen / immunology*
Benzodiazepines / pharmacology*
Drug Evaluation, Preclinical / methods
Humans
Multiple Myeloma / drug therapy*
Pyrroles / pharmacology*
Stem Cells / drug effects*

Substances

Antibodies
B-Cell Maturation Antigen
Pyrroles
pyrrolo(2,1-c)(1,4)benzodiazepine
Benzodiazepines